ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · EFO_0010282

gastrointestinal disease

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. gastrointestinal disease. Diseases, record EFO_0010282. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0010282

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
gastrointestinal disease
Open Targets
Open Targets ID
EFO_0010282
Open Targets
Disease Ontology
DOID:77
Disease Ontology
Highest stage of its drugs
Approval, for 78 of its 97 drugs, from ATC and TTD
Open Targets

Drugs97

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
ALVERINECHEMBL253371Small moleculeApprovalATC200Drugs and targets
CISAPRIDECHEMBL1729Small moleculeApprovalATC200Drugs and targets
DOMPERIDONECHEMBL219916Small moleculeApprovalATC and TTD200Drugs and targets
HOMATROPINE METHYLBROMIDECHEMBL1200851Small moleculeApprovalATC200Drugs and targets
HYOSCYAMINECHEMBL1331216Small moleculeApprovalATC and TTD200Drugs and targets
MEPENZOLATECHEMBL524004Small moleculeApprovalATC and TTD200Drugs and targets
OXYPHENONIUMCHEMBL1201286Small moleculeApprovalATC200Drugs and targets
(2-BENZHYDRYLOXYETHYL)DIETHYL-METHYLAMMONIUM IODIDECHEMBL3707204Small moleculeApprovalATC100Drugs and targets
ACOTIAMIDECHEMBL2107723Small moleculeApprovalATC100Drugs and targets
ALIZAPRIDECHEMBL290194Small moleculeApprovalATC100Drugs and targets

1 to 10 of 97

See all 97 drugs

Targets69

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
CHRM1Muscarinic acetylcholine receptor M113Muscarinic acetylcholine receptor M1 antagonistApprovalhttps://conductscience.org/library/genes/1128Drugs and targets
CHRM3Muscarinic acetylcholine receptor M313Muscarinic acetylcholine receptor M3 antagonistApprovalhttps://conductscience.org/library/genes/1131Drugs and targets
DRD2D(2) dopamine receptor6Dopamine D2 receptor antagonistApprovalhttps://conductscience.org/library/genes/1813Drugs and targets
HTR45-hydroxytryptamine receptor 45Serotonin 4 (5-HT4) receptor agonistApprovalhttps://conductscience.org/library/genes/3360Drugs and targets
HTR3A5-hydroxytryptamine receptor 3A4Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonistApprovalhttps://conductscience.org/library/genes/3359Drugs and targets
ACHEAcetylcholinesterase2Acetylcholinesterase inhibitorApprovalhttps://conductscience.org/library/genes/43Drugs and targets
CHRM2Muscarinic acetylcholine receptor M22Muscarinic acetylcholine receptor M2 antagonistApprovalhttps://conductscience.org/library/genes/1129Drugs and targets
HTR3BSerotonin 3 (5-HT3) receptor2Serotonin 3 (5-HT3) receptor antagonistApprovalhttps://conductscience.org/library/genes/9177Drugs and targets
OPRM1Mu-type opioid receptor2Mu opioid receptor antagonist; Opioid receptors; mu/kappa/delta agonistApprovalhttps://conductscience.org/library/genes/4988Drugs and targets
CACNA1AVoltage-gated calcium channel1Voltage-gated calcium channel blockerApprovalhttps://conductscience.org/library/genes/773Drugs and targets

1 to 10 of 69

See all 69 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT04150250Cholera Anti-Secretory Treatment TrialPhase 2472021-03-25CholeraIOWH-032Open Targets' reading of its recordClinicalTrials.gov
NCT00229944Single Dose Azithromycin in the Treatment of Adult CholeraPhase 3220CholeraAZITHROMYCIN, CIPROFLOXACINOpen Targets' reading of its recordClinicalTrials.gov
NCT00741052Ciprofloxacin Multiple Dose for Adult CholeraPhase 3218CholeraAZITHROMYCIN, CIPROFLOXACINOpen Targets' reading of its recordClinicalTrials.gov
NCT00142272Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical TrialPhase 3180CholeraCIPROFLOXACIN, ERYTHROMYCINOpen Targets' reading of its recordClinicalTrials.gov
NCT04593836Antiperistaltic Effect and Safety of L-menthol in the Elderly With Contraindication to BuscopanPhase 360Upper Gastrointestinal EndoscopyLEVOMENTHOLOpen Targets' reading of its recordClinicalTrials.gov
NCT05880459Sedation in Patients Undergoing GIT EndoscopyEarly phase 160Sedation for Patients Undergoing GIT EndoscopyMAGNESIUM SULFATE, NALBUPHINE, PROPOFOLOpen Targets' reading of its recordClinicalTrials.gov
NCT00226616Zinc Supplementation in Cholera PatientsPhase 3CholeraERYTHROMYCINOpen Targets' reading of its recordClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
iOWH032 vs Placebo: Number of Participants With Treatment-emergent Serious Adverse Events0 of 231 of 2447NCT04150250Trial comparisons
iOWH032 vs Placebo: deaths from any cause0 of 230 of 2447NCT04150250Trial comparisons
iOWH032 vs Placebo: serious adverse events0 of 231 of 2447NCT04150250Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
16760445RESULT1PubMed
35729250DERIVED1PubMed
34793441DERIVED1PubMed
18184631DERIVED1PubMed
16182896DERIVED1PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0010282

GET https://conductscience.org/api/diseases/v1/EFO_0010282/drugs?page=2

API referenceFor AI assistants